Key result
Natural mutations in the receptor binding domain of civet coronaviruses reduced viral entry efficiency into human ACE2 cells by 90 to 95% compared to SARS-CoV and conferred significant resistance to cross-neutralization.
Population
Mice immunized with DNA vaccines constructed from four civet S genes; cells expressing human receptor ACE2…
Comparison
DNA vaccines constructed with four civet S genes vs SARS-CoV S gene vaccines / autologous vs…
Design
Preclinical
Authors
Loading...
May limit SARS-CoV vaccine cross-protection against civet CoVs; hypothesis-generating for broader coronavirus surveillance.
Natural mutations in the RBD of civet-CoVs significantly reduce cross-neutralization with SARS-CoV, suggesting SARS vaccines should be designed to provide cross-protection against divergent civet CoVs.
Liu et al. (2007) studied Severe Acute Respiratory Syndrome (SARS). Civet-CoV S glycoprotein DNA vaccines vs. SARS-CoV DNA vaccine was evaluated on Viral entry efficiency and cross-neutralization. Natural mutations in the receptor binding domain of civet coronaviruses reduced viral entry efficiency into human ACE2 cells by 90 to 95% compared to SARS-CoV and conferred significant resistance to cross-neutralization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: